MX2021002995A - Inhibidores del inhibidor 1 de activador de plasminogeno (pai-1) y usos de los mismos. - Google Patents
Inhibidores del inhibidor 1 de activador de plasminogeno (pai-1) y usos de los mismos.Info
- Publication number
- MX2021002995A MX2021002995A MX2021002995A MX2021002995A MX2021002995A MX 2021002995 A MX2021002995 A MX 2021002995A MX 2021002995 A MX2021002995 A MX 2021002995A MX 2021002995 A MX2021002995 A MX 2021002995A MX 2021002995 A MX2021002995 A MX 2021002995A
- Authority
- MX
- Mexico
- Prior art keywords
- pai
- inhibitors
- plasminogen activator
- activator inhibitor
- prevention
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Dispersion Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
- Biophysics (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862731074P | 2018-09-13 | 2018-09-13 | |
| PCT/US2019/050849 WO2020056160A1 (en) | 2018-09-13 | 2019-09-12 | Plasminogen activator inhibitor 1 (pai-1) inhibitors and uses therefor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021002995A true MX2021002995A (es) | 2021-07-15 |
Family
ID=68052024
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021002995A MX2021002995A (es) | 2018-09-13 | 2019-09-12 | Inhibidores del inhibidor 1 de activador de plasminogeno (pai-1) y usos de los mismos. |
| MX2025004193A MX2025004193A (es) | 2018-09-13 | 2021-03-12 | Inhibidores del inhibidor 1 de activador de plasminogeno (pai-1) y usos de los mismos |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2025004193A MX2025004193A (es) | 2018-09-13 | 2021-03-12 | Inhibidores del inhibidor 1 de activador de plasminogeno (pai-1) y usos de los mismos |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220105068A1 (https=) |
| EP (1) | EP3849539A1 (https=) |
| JP (2) | JP2021535925A (https=) |
| KR (2) | KR102884331B1 (https=) |
| CN (2) | CN113056268A (https=) |
| AU (1) | AU2019338459B2 (https=) |
| BR (1) | BR112021004542A2 (https=) |
| CA (1) | CA3112558A1 (https=) |
| IL (1) | IL281450A (https=) |
| MX (2) | MX2021002995A (https=) |
| SG (1) | SG11202102478SA (https=) |
| WO (1) | WO2020056160A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017360346B2 (en) | 2016-11-21 | 2023-11-23 | Eirion Therapeutics, Inc. | Transdermal delivery of large agents |
| CN113155987B (zh) * | 2020-12-28 | 2023-06-06 | 浙江工商大学 | 一种微针贴片及其制备方法、应用 |
| AU2024344613A1 (en) | 2023-09-18 | 2026-04-23 | Eirion Therapeutics, Inc. | Topical compositions and uses of pai-1 inhibitors |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US296006A (en) | 1884-04-01 | John hoefleb | ||
| US4270537A (en) | 1979-11-19 | 1981-06-02 | Romaine Richard A | Automatic hypodermic syringe |
| US4886499A (en) | 1986-12-18 | 1989-12-12 | Hoffmann-La Roche Inc. | Portable injection appliance |
| GB8704027D0 (en) | 1987-02-20 | 1987-03-25 | Owen Mumford Ltd | Syringe needle combination |
| FR2638359A1 (fr) | 1988-11-03 | 1990-05-04 | Tino Dalto | Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau |
| US5008110A (en) | 1988-11-10 | 1991-04-16 | The Procter & Gamble Company | Storage-stable transdermal patch |
| US5190521A (en) | 1990-08-22 | 1993-03-02 | Tecnol Medical Products, Inc. | Apparatus and method for raising a skin wheal and anesthetizing skin |
| US5527288A (en) | 1990-12-13 | 1996-06-18 | Elan Medical Technologies Limited | Intradermal drug delivery device and method for intradermal delivery of drugs |
| SE9102652D0 (sv) | 1991-09-13 | 1991-09-13 | Kabi Pharmacia Ab | Injection needle arrangement |
| US5328483A (en) | 1992-02-27 | 1994-07-12 | Jacoby Richard M | Intradermal injection device with medication and needle guard |
| US6010715A (en) | 1992-04-01 | 2000-01-04 | Bertek, Inc. | Transdermal patch incorporating a polymer film incorporated with an active agent |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| IT1261849B (it) | 1993-09-02 | 1996-06-03 | Avantgarde Spa | Dispositivo medico per la somministrazione di principi attivi o farmaci a bassissimo dosaggio, in particolare di farmaci omeopatici. |
| US5948433A (en) | 1997-08-21 | 1999-09-07 | Bertek, Inc. | Transdermal patch |
| IT1298087B1 (it) | 1998-01-08 | 1999-12-20 | Fiderm S R L | Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni |
| US5965154A (en) | 1998-03-17 | 1999-10-12 | Plc Holding, L.L.C. | Adhesive matrix type transdermal patch and method of manufacturing same |
| US6503231B1 (en) | 1998-06-10 | 2003-01-07 | Georgia Tech Research Corporation | Microneedle device for transport of molecules across tissue |
| US6611707B1 (en) | 1999-06-04 | 2003-08-26 | Georgia Tech Research Corporation | Microneedle drug delivery device |
| WO2001051085A1 (en) * | 2000-01-14 | 2001-07-19 | Tanox, Inc. | Use of antagonists of plasminogen activator inhibitor-1 (pai-1) for the treatment of asthma and chronic obstructive pulmonary disease |
| US6908453B2 (en) | 2002-01-15 | 2005-06-21 | 3M Innovative Properties Company | Microneedle devices and methods of manufacture |
| WO2003071267A1 (en) * | 2002-02-19 | 2003-08-28 | Vanderbilt University | Therapeutic methods employing pai-1 inhibitors and transgenic non-human animal for screening candidate pai-1 inhibitors |
| EP1509236A4 (en) * | 2002-05-13 | 2008-07-30 | Children S Hospital Los Angele | TREATMENT AND PREVENTION OF ABNORMAL SCALING IN KELOIDS AND OTHER SKIN OR INTERNAL WOUNDS OR LESIONS |
| WO2006018024A2 (en) * | 2004-08-18 | 2006-02-23 | Ace Aps | Cosmetic and pharmaceutical compositions comprising ace inhibitors and/or angiotensin ii receptor antagonists |
| BRPI0619134B8 (pt) | 2005-12-01 | 2021-05-25 | Univ Massachusetts Lowell | nanoemulsão, composição farmacêutica, composição, métodos cosméticos para o tratamento de rugas, linhas faciais e/ou linhas do pescoço, e de retardar o início das rugas, linhas faciais e/ou linhas do pescoço, e, método de fabricação de uma nanoemulsão |
| EP2015773A4 (en) | 2006-04-27 | 2010-05-05 | Anterios Inc | EXAMINATION OF THE EFFECTS OF TOPICAL ADMINISTRATION OF CHEMICALLY DENOMINATING PHARMACEUTICALS |
| WO2008070538A2 (en) | 2006-12-01 | 2008-06-12 | Anterios, Inc. | Micellar nanoparticles comprising botulinum toxin |
| WO2009123241A1 (ja) * | 2008-03-31 | 2009-10-08 | 株式会社レナサイエンス | プラスミノーゲンアクチベーターインヒビター－１阻害剤 |
| MX379265B (es) | 2008-06-26 | 2025-03-11 | Anterios Inc | Aplicacion dérmica de toxina botulínica en nanoemulsiones para usarse en el tratamiento de trastornos de la piel. |
| US20120114745A1 (en) * | 2009-06-26 | 2012-05-10 | Nam-Mew Pui | Method for treating or ameliorating mucocutaneous or ocular toxicities |
| EP2667854B1 (en) | 2011-01-24 | 2019-01-16 | Anterios, Inc. | Nanoparticle compositions |
| KR20140005998A (ko) | 2011-01-24 | 2014-01-15 | 안테리오스, 인코퍼레이티드 | 나노입자 조성물, 이의 제형, 및 그의 용도 |
| WO2013096026A1 (en) | 2011-12-21 | 2013-06-27 | 3M Innovative Properties Company | Transdermal adhesive patch assembly with removable microneedle array and method of using same |
-
2019
- 2019-09-12 BR BR112021004542-2A patent/BR112021004542A2/pt unknown
- 2019-09-12 EP EP19773718.2A patent/EP3849539A1/en active Pending
- 2019-09-12 WO PCT/US2019/050849 patent/WO2020056160A1/en not_active Ceased
- 2019-09-12 KR KR1020217010851A patent/KR102884331B1/ko active Active
- 2019-09-12 US US17/274,948 patent/US20220105068A1/en active Pending
- 2019-09-12 CN CN201980074633.8A patent/CN113056268A/zh active Pending
- 2019-09-12 MX MX2021002995A patent/MX2021002995A/es unknown
- 2019-09-12 CA CA3112558A patent/CA3112558A1/en active Pending
- 2019-09-12 JP JP2021514401A patent/JP2021535925A/ja active Pending
- 2019-09-12 KR KR1020257037244A patent/KR20250163416A/ko active Pending
- 2019-09-12 AU AU2019338459A patent/AU2019338459B2/en active Active
- 2019-09-12 SG SG11202102478SA patent/SG11202102478SA/en unknown
- 2019-09-12 CN CN202511057022.6A patent/CN120983628A/zh active Pending
-
2021
- 2021-03-11 IL IL281450A patent/IL281450A/en unknown
- 2021-03-12 MX MX2025004193A patent/MX2025004193A/es unknown
-
2024
- 2024-09-12 JP JP2024158484A patent/JP2025011085A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112021004542A2 (pt) | 2021-06-08 |
| CN113056268A (zh) | 2021-06-29 |
| KR20210057141A (ko) | 2021-05-20 |
| CN120983628A (zh) | 2025-11-21 |
| WO2020056160A1 (en) | 2020-03-19 |
| KR102884331B1 (ko) | 2025-11-13 |
| JP2025011085A (ja) | 2025-01-23 |
| AU2019338459B2 (en) | 2025-07-10 |
| CA3112558A1 (en) | 2020-03-19 |
| KR20250163416A (ko) | 2025-11-20 |
| MX2025004193A (es) | 2025-05-02 |
| IL281450A (en) | 2021-04-29 |
| JP2021535925A (ja) | 2021-12-23 |
| EP3849539A1 (en) | 2021-07-21 |
| SG11202102478SA (en) | 2021-04-29 |
| AU2019338459A1 (en) | 2021-04-08 |
| US20220105068A1 (en) | 2022-04-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2021000151A2 (es) | Inhibidores de pd-1/pd-l1 | |
| CL2021002099A1 (es) | Combinación farmacéutica que comprende tno155 y ribociclib. | |
| CL2020002082A1 (es) | Inhibidores pd-1/pd-l1. | |
| PH12021500005A1 (en) | Sulfonimidamide compounds as inhibitors of interleukin-1 activity | |
| CL2019002895A1 (es) | Inhibidores de pd-1/pd-l1. | |
| ZA202007007B (en) | Mcl-1 inhibitors | |
| PH12021552848A1 (en) | Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereof | |
| CO2019007298A2 (es) | Inhibidores de tgfβ1 isoforma-específicos contexto-permisivos y uso de los mismos | |
| CO2021004141A2 (es) | Moduladores de la expresión de pnpla3 | |
| EA202091964A1 (ru) | КОМБИНИРОВАННЫЙ ПРОДУКТ НА ОСНОВЕ ИНГИБИТОРА Bcl-2 И ИНГИБИТОРА MDM2 И ЕГО ПРИМЕНЕНИЕ В ПРЕДУПРЕЖДЕНИИ И/ИЛИ ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ | |
| MX2021002995A (es) | Inhibidores del inhibidor 1 de activador de plasminogeno (pai-1) y usos de los mismos. | |
| CO2019011265A2 (es) | Moduladores de la expresión de pcsk9 | |
| CR20200631A (es) | Modulares de la expresión de apol1 | |
| CO2022000214A2 (es) | Composiciones para el tratamiento de la pérdida del cabello | |
| MX2022003689A (es) | Metodos y composiciones para el tratamiento contra una enfermedad o trastorno. | |
| MX2024002857A (es) | Milvexian para la prevencion y el tratamiento de trastornos tromboembolicos. | |
| CO2022000266A2 (es) | Inhibidores de enzimas | |
| UY38352A (es) | Inhibidores de integrina alfavbeta6 | |
| ZA202108579B (en) | Inhibitors of notch signalling pathway and use thereof in treatment of cancers | |
| MX2024012565A (es) | Composiciones farmaceuticas de mosunetuzumab y metodos de uso | |
| MX2022006312A (es) | Inhibidores del receptor de hidrocarburos de arilo (ahr) y usos de los mismos. | |
| MX2024014079A (es) | Inhibidores de la proteina cinasa activada por mitogeno (mek) y usos de estos | |
| MX2021003263A (es) | Combinacion de un antagonista de proteina de muerte programada 1 (pd-1), un inhibidor de ataxia telangiectasia y proteina relacionada con rad3 (atr) y un agente de platino para el tratamiento de cancer. | |
| CO2021007006A2 (es) | Moduladores de la expresión de irf5 | |
| MX2025003991A (es) | Usos de inhibidores del inhibidor del activador de plasminogeno tipo 1 (pai-1) |